Verho M - Search Results

1

Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease.

Winkelmann BR, Nauck M, Klein B, Russ AP, Böhm BO, Siekmeier R, Ihnken K, Verho M, Gross W, März W. Winkelmann BR, et al. Among authors: verho m. Ann Intern Med. 1996 Jul 1;125(1):19-25. doi: 10.7326/0003-4819-125-1-199607010-00004. Ann Intern Med. 1996. PMID: 8644984

2

ACE*D and cardiovascular disease.

Winkelmann BR, Verho M. Winkelmann BR, et al. Among authors: verho m. Circulation. 1997 Aug 5;96(3):1050-2. Circulation. 1997. PMID: 9264525 No abstract available.

3

Acute myocardial infarction in a young South African Indian-based population: patient characteristics on admission and gender-specific risk factor prevalence.

Ranjith N, Verho NK, Verho M, Winkelmann BR. Ranjith N, et al. Among authors: verho m. Curr Med Res Opin. 2002;18(4):242-8. doi: 10.1185/030079902125000624. Curr Med Res Opin. 2002. PMID: 12201626

4

Pharmacokinetics of levofloxacin in comparison to the racemic mixture of ofloxacin in man.

Verho M, Malerczyk V, Damm D, Lehr KH. Verho M, et al. Drug Metabol Drug Interact. 1996;13(1):57-67. doi: 10.1515/dmdi.1996.13.1.57. Drug Metabol Drug Interact. 1996. PMID: 8902431 Clinical Trial.

5

Relative bioavailability of ofloxacin tablets in comparison to oral solution.

Malerczyk V, Verho M, Korn A, Rangoonwala R. Malerczyk V, et al. Among authors: verho m. Curr Med Res Opin. 1987;10(8):514-20. doi: 10.1185/03007998709108959. Curr Med Res Opin. 1987. PMID: 3479296 Clinical Trial.

6

Effects of felodipine ER, a dihydropyridine calcium antagonist, on blood pressure and serum lipids.

Reuter MK, Lorenz H, Verho P, Smith N, Degen A, Verho M. Reuter MK, et al. Among authors: verho m. Curr Med Res Opin. 1998;14(2):97-103. doi: 10.1185/03007999809113348. Curr Med Res Opin. 1998. PMID: 9704199 Clinical Trial.

7

Dose linearity testing of intravenous ofloxacin, a novel gyrase inhibitor.

Verho M, Korn A, Badian M, Malerczyk V, Waldhäusl W. Verho M, et al. Chemotherapy. 1988;34(3):170-7. doi: 10.1159/000238567. Chemotherapy. 1988. PMID: 3166420

8

Absence of interaction between ramipril, a new ACE-inhibitor, and phenprocoumon, an anticoagulant agent.

Verho M, Malerczyk V, Grötsch H, Zenbil I. Verho M, et al. Pharmatherapeutica. 1989;5(6):392-9. Pharmatherapeutica. 1989. PMID: 2531901 Clinical Trial.

9

Absence of crystalluria and estimation of renal parameters after oral and intravenous ofloxacin as compared to placebo in healthy volunteers.

Verho M, Malerczyk V, Grötsch H, Lorenz H. Verho M, et al. Drugs Exp Clin Res. 1988;14(8):539-45. Drugs Exp Clin Res. 1988. PMID: 2907877 Clinical Trial.

10

Safety, tolerance and pharmacokinetics of 2.0 g cefpirome (HR 810) after single and multiple dosing.

Badian M, Malerczyk V, Collins JD, Dixon GT, Verho M, Eckert HG. Badian M, et al. Among authors: verho m. Chemotherapy. 1988;34(5):367-73. doi: 10.1159/000238594. Chemotherapy. 1988. PMID: 3180904

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

57 results

Search Page